ALLO

Allogene Therapeutics Inc (ALLO) | Rumor.io

Allogene Therapeutics

ALLO

Attention (50-day avg)0%

Attention rank (50-day avg)#1,938

Bullish sentiment (50-day avg)91%

Price to earnings ratio-1.87

Market capitalization563.2M

Earnings per share-0.66

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-190.9M

Social

What share of all stock conversation is about ALLO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% -0.01

Jul 22

Allogene Therapeutics' ($ALLO) whale data shows 105 whales are long, with a total long position of $20.81M, compared to $9.27M in shorts, and 99.04% of whale longs are currently in profit.
The stock has continued to respect its ascending support trendline, with buyers defending every pullback, suggesting a bullish structure remains intact.
Allogene Therapeutics is working on a new treatment, ALLO-329, an investigational allogeneic CART powered by Dagger technology, which aims to redefine autoimmune disease treatment.

Generated by AI

Sentiment

Of the messages about ALLO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +6.67	98.46% +11.58	78.21% -8.8
Bearish	0%	0% -6.67	1.54% -11.58	21.79% +8.8

Bullish· Jun 8

$ALLO has shown a strong 6X gain, from $0.09 to $0.56, indicating a significant increase in value.
The asset has broken out of its Darvas box and retested successfully, with a strong price action and a potential 100-200% bullish rally.
$ALLO has a strong support level at $0.3086, which has held firm, and is expected to reclaim $0.51, with further targets at $0.6837 and potentially $1.10.

Bearish· May 14

$ALLO is facing a corrupt market with widespread fraud, deception, and price manipulation, making it an unsuitable environment for trading.
The company's subsidiary, Neurovia AI, has released its core technology platform, NeuroStream, but this development may not be enough to drive significant growth for Allogene Therapeutics.
The market is comparing Allogene's valuation unfavorably to that of Sellas, a smaller bio company with limited resources and a delayed Phase 3 readout, highlighting potential overvaluation concerns for Allogene.

Generated by AI

Topics

Of the messages about ALLO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	20.51%	35.27%
Technical Analysis	—	—	79.49%	42.23%
Earnings	—	—	0%	1.45%
Analysts	—	—	0%	17.02%
Controversies	—	—	0%	0.28%
Macro	—	—	0%	3.75%

Analysts· Oct 8

Allogene Therapeutics' stock was downgraded by Goldman Sachs from Buy to Neutral with a new price target of $20.
B. Riley analysts view the clinical hold on Allogene Therapeutics' CAR T cell therapy as a "speed bump" in the therapy's development and maintained a Buy rating with a price target of $30.
Analysts' consensus on Allogene Therapeutics is overwhelmingly positive, with 13 analysts analyzed and a 94% Buy consensus.

Announcements· Apr 13

Allogene Therapeutics ($ALLO) reports interim futility analysis from pivotal ALPHA3 trial, showing 58.3% MRD clearance with cemacabtagene ansegedleucel (cema-cel) vs. 16.7% in observation arm in first-line consolidation large B-cell lymphoma (LBCL).
The company expects to use the net proceeds from a $175M common stock offering for general corporate purposes, including clinical trial expenses, research and development expenses, and capital expenditures.
Allogene's off-the-shelf CAR-T, cema-cel, shows a favorable safety profile compared with the observation arm in first-line consolidation LBCL, and may have found its role in delaying relapse in lymphoma.

Controversies· Jan 10

Allogene Therapeutics ($ALLO) had its FDA clinical hold lifted across all AlloCAR T clinical trials, removing a significant roadblock to its cancer cell therapy development.
The hold was lifted after the FDA determined a chromosomal abnormality found in the trials was unrelated to the company's manufacturing process and had no clinical significance.
The news sent Allogene's stock price plummeting 13% to $11.6, down from $24 before the clinical hold was announced.

Technical Analysis· Feb 21

$ALLO is attempting a key structural shift on the daily timeframe, pushing back above a major horizontal resistance that previously capped price for months.
The stock is in a short-term downtrend but may soon grab the lower liquidity below the levels, and a breakout above 0.132 could lead to continuation toward new highs.
The stock is currently in a key zone and may continue to decline further, but a long position is also possible with entry at 0.1340 – 0.1390 and targets at 0.1550, 0.1800, and 0.2100.

Generated by AI

Community

Of the messages about ALLO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	6.67%	39.68%	45.12%
Newcomers	100%	93.33%	60.32%	54.88%

Regulars· Nov 6

Tomorrow is expected to be a significant day for Allogene Therapeutics, with some users speculating about its potential impact on the company.
Allogene Therapeutics has released its Q3 2025 corporate update and business highlights, which includes a Q3 call, and its Q3 2025 financial results and business update are available.
Allogene Therapeutics has reported a significant earnings beat, with its adj. EPS at $(0.19) and a YoY increase of 40.63% from $(0.32).

Newcomers· Feb 25

New investors are initiating positions in $ALLO, with some keen to buy at current prices.
There is concern about the company's cash runway and potential for dilution.
The stock's price movement is being closely watched, with some predicting a 5% increase in the near future.

Generated by AI

News

Citizens reiterates Allogene stock rating on CAR T pipeline progress

15d agoInvesting.com

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

18d agoYahoo Finance

Allogene at Citi summit: mrD strategy and cash runway in focus

20d agoInvesting.com

Allogene Stock: If MRD Holds, This Becomes A Completely Different Company (NASDAQ:ALLO)

Allogene Therapeutics maintains a $423.6M cash balance, disciplined cost controls, and a runway into 2029. Read why I rate ALLO stock a Buy.

23d agoSeeking Alpha

Allogene Therapeutics Announces Retirement of Chief Financial Officer

Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.

26d agoThe Globe and Mail

Allogene CFO Geoffrey Parker to retire in November

27d agoInvesting.com

Also Discussed

Investors talking about ALLO also mention

#	Name	Attention
1	HUDSON PACIFIC PROPERTIES INCHPP	0%new
2	Corgi Total U.S. Market 2x Daily ETFUSX	0%0
3	Abrdn Healthcare Opportunities FundTHQ	0.01%new
4	Quanterix CorporationQTRX	0%new
5	Crane NXT, Co.CXT	0%0
6	Mira Pharmaceuticals, Inc.MIRA	0%0
7	Aberdeen Multi-Market Income FundMMT	0%new
8	ELP - Companhia Paranaense de Energia - COPEL	——
9	Humacyte Inc.HUMA	0%0
10	Invesco S&P SmallCap 600 Pure Value ETFRZV	0%0

Allogene Therapeutics Inc

Healthcare
Biotechnology

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, CAR T cell therapies for cancer and autoimmune disease. The company’s current work centers on investigational off-the-shelf cell therapy candidates designed to be manufactured from healthy donor cells and delivered more readily to patients than individualized treatments. Its pipeline includes programs targeting blood cancers, solid tumors, and autoimmune disorders, with emphasis on areas such as large B-cell lymphoma, renal cell carcinoma, and other oncology indications. Allogene Therapeutics also develops supporting technologies and manufacturing capabilities that are intended to improve the consistency, scalability, and accessibility of its cell therapy platform. Headquartered in South San Francisco, California, Allogene Therapeutics plays a specialized role in the immuno-oncology market as a developer of next-generation cell therapies for complex diseases.

Website

Location

210 East Grand Avenue

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about ALLO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% -0.01

Jul 22

Allogene Therapeutics' ($ALLO) whale data shows 105 whales are long, with a total long position of $20.81M, compared to $9.27M in shorts, and 99.04% of whale longs are currently in profit.
The stock has continued to respect its ascending support trendline, with buyers defending every pullback, suggesting a bullish structure remains intact.
Allogene Therapeutics is working on a new treatment, ALLO-329, an investigational allogeneic CART powered by Dagger technology, which aims to redefine autoimmune disease treatment.

Generated by AI

Sentiment

Of the messages about ALLO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +6.67	98.46% +11.58	78.21% -8.8
Bearish	0%	0% -6.67	1.54% -11.58	21.79% +8.8

Bullish· Jun 8

$ALLO has shown a strong 6X gain, from $0.09 to $0.56, indicating a significant increase in value.
The asset has broken out of its Darvas box and retested successfully, with a strong price action and a potential 100-200% bullish rally.
$ALLO has a strong support level at $0.3086, which has held firm, and is expected to reclaim $0.51, with further targets at $0.6837 and potentially $1.10.

Bearish· May 14

$ALLO is facing a corrupt market with widespread fraud, deception, and price manipulation, making it an unsuitable environment for trading.
The company's subsidiary, Neurovia AI, has released its core technology platform, NeuroStream, but this development may not be enough to drive significant growth for Allogene Therapeutics.
The market is comparing Allogene's valuation unfavorably to that of Sellas, a smaller bio company with limited resources and a delayed Phase 3 readout, highlighting potential overvaluation concerns for Allogene.

Generated by AI

Topics

Of the messages about ALLO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	20.51%	35.27%
Technical Analysis	—	—	79.49%	42.23%
Earnings	—	—	0%	1.45%
Analysts	—	—	0%	17.02%
Controversies	—	—	0%	0.28%
Macro	—	—	0%	3.75%

Analysts· Oct 8

Allogene Therapeutics' stock was downgraded by Goldman Sachs from Buy to Neutral with a new price target of $20.
B. Riley analysts view the clinical hold on Allogene Therapeutics' CAR T cell therapy as a "speed bump" in the therapy's development and maintained a Buy rating with a price target of $30.
Analysts' consensus on Allogene Therapeutics is overwhelmingly positive, with 13 analysts analyzed and a 94% Buy consensus.

Announcements· Apr 13

Allogene Therapeutics ($ALLO) reports interim futility analysis from pivotal ALPHA3 trial, showing 58.3% MRD clearance with cemacabtagene ansegedleucel (cema-cel) vs. 16.7% in observation arm in first-line consolidation large B-cell lymphoma (LBCL).
The company expects to use the net proceeds from a $175M common stock offering for general corporate purposes, including clinical trial expenses, research and development expenses, and capital expenditures.
Allogene's off-the-shelf CAR-T, cema-cel, shows a favorable safety profile compared with the observation arm in first-line consolidation LBCL, and may have found its role in delaying relapse in lymphoma.

Controversies· Jan 10

Allogene Therapeutics ($ALLO) had its FDA clinical hold lifted across all AlloCAR T clinical trials, removing a significant roadblock to its cancer cell therapy development.
The hold was lifted after the FDA determined a chromosomal abnormality found in the trials was unrelated to the company's manufacturing process and had no clinical significance.
The news sent Allogene's stock price plummeting 13% to $11.6, down from $24 before the clinical hold was announced.

Technical Analysis· Feb 21

$ALLO is attempting a key structural shift on the daily timeframe, pushing back above a major horizontal resistance that previously capped price for months.
The stock is in a short-term downtrend but may soon grab the lower liquidity below the levels, and a breakout above 0.132 could lead to continuation toward new highs.
The stock is currently in a key zone and may continue to decline further, but a long position is also possible with entry at 0.1340 – 0.1390 and targets at 0.1550, 0.1800, and 0.2100.

Generated by AI

Community

Of the messages about ALLO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	6.67%	39.68%	45.12%
Newcomers	100%	93.33%	60.32%	54.88%

Regulars· Nov 6

Tomorrow is expected to be a significant day for Allogene Therapeutics, with some users speculating about its potential impact on the company.
Allogene Therapeutics has released its Q3 2025 corporate update and business highlights, which includes a Q3 call, and its Q3 2025 financial results and business update are available.
Allogene Therapeutics has reported a significant earnings beat, with its adj. EPS at $(0.19) and a YoY increase of 40.63% from $(0.32).

Newcomers· Feb 25

New investors are initiating positions in $ALLO, with some keen to buy at current prices.
There is concern about the company's cash runway and potential for dilution.
The stock's price movement is being closely watched, with some predicting a 5% increase in the near future.

Generated by AI

Allogene Therapeutics

Social

Jul 22

Bullish· Jun 8

Bearish· May 14

Analysts· Oct 8

Announcements· Apr 13

Controversies· Jan 10

Technical Analysis· Feb 21

Regulars· Nov 6

Newcomers· Feb 25

Citizens reiterates Allogene stock rating on CAR T pipeline progress

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene at Citi summit: mrD strategy and cash runway in focus

Allogene Stock: If MRD Holds, This Becomes A Completely Different Company (NASDAQ:ALLO)

Allogene Therapeutics Announces Retirement of Chief Financial Officer

Allogene CFO Geoffrey Parker to retire in November

Also Discussed

Allogene Therapeutics Inc

Company Information

Location

Citizens reiterates Allogene stock rating on CAR T pipeline progress

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene at Citi summit: mrD strategy and cash runway in focus

Allogene Stock: If MRD Holds, This Becomes A Completely Different Company (NASDAQ:ALLO)

Allogene Therapeutics Announces Retirement of Chief Financial Officer

Allogene CFO Geoffrey Parker to retire in November

Also Discussed

Social

Jul 22

Bullish· Jun 8

Bearish· May 14

Analysts· Oct 8

Announcements· Apr 13

Controversies· Jan 10

Technical Analysis· Feb 21

Regulars· Nov 6

Newcomers· Feb 25